Sugi Predict

Sugi Predict / Targets / PDE4C

PDE4C

3',5'-cyclic-AMP phosphodiesterase 4C · Q08493 · PDE4C on Sugi Atlas →

214,495 patent compounds predicted against PDE4C, 110,600 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Cilomilast Cilomilast (SCHEMBL26372) 1.00 19/20
Cilomilast Cilomilast (SCHEMBL27515) 1.00 19/20
Cilomilast Cilomilast (SCHEMBL27516) 1.00 19/20
SCHEMBL84865 SCHEMBL84865 1.00 19/20
SCHEMBL121198 SCHEMBL121198 0.79 19/20
SCHEMBL84940 SCHEMBL84940 0.69 19/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL74285) 0.59 18/20
SCHEMBL141225 SCHEMBL141225 0.52 18/20
SCHEMBL143156 SCHEMBL143156 0.51 18/20
SCHEMBL141742 SCHEMBL141742 0.50 18/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL72328) 0.49 18/20
Piroximone Piroximone (SCHEMBL119758) 0.64 17/20
SCHEMBL74891 SCHEMBL74891 0.63 17/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL74596) 0.58 17/20
SCHEMBL85519 SCHEMBL85519 0.56 17/20
SCHEMBL73157 SCHEMBL73157 0.56 17/20
SCHEMBL73542 SCHEMBL73542 0.54 17/20
SCHEMBL73048 SCHEMBL73048 0.54 17/20
SCHEMBL84496 SCHEMBL84496 0.53 17/20
SCHEMBL84495 SCHEMBL84495 0.52 17/20

Clinical trials — most relevant to PDE4C by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis PHASE4COMPLETED
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis PHASE4COMPLETED
Safety And Efficacy Of L-Arginine Monotherapy Versus Tadalafil Monotherapy Versus Their Combination In Men With Erectile Dysfunction; A Prospective Randomized Study PHASE4COMPLETED
Switching of Sildenafil to Riociguat in CTEPH Patients PHASE4RECRUITING
Cardiovascular Effects of Chronic Sildenafil in Men With Type 2 Diabetes PHASE4COMPLETED
Bosentan in Treatment of Pulmonary Arterial Hypertension PHASE4COMPLETED
Use of Sildenafil Citrate in Management of Mild Pre-eclampsia PHASE2/PHASE3UNKNOWN
Chronic Sildenafil Treatment in Heart Failure PHASE3COMPLETED
The Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension PHASE3COMPLETED
Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage PHASE3NOT_YET_RECRUITING
Title: Evaluation of a Novel PET Radioligand for Phosphodiesterase-4D (PDE4D) PHASE1/PHASE2COMPLETED
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia PHASE1/PHASE2COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old PHASE2ACTIVE_NOT_RECRUITING
The Controlled Trial of Apremilast for Rheumatoid Arthritis Treatment (CARAT) PHASE2COMPLETED
Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm PHASE2WITHDRAWN
PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction PHASE2COMPLETED
Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients PHASE1/PHASE2COMPLETED
Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease PHASE2COMPLETED
Cilostazol and Its Effects on Resumption of Meiosis in the Human Ovary PHASE2COMPLETED
Safety Study of the Effect of Scelectium Tortuosum (as Zembrin®)in Aged Normals PHASE1COMPLETED
PET Whole Body Biodistribution and Test Retest Bain Imaging Studies Using a Phosphodiesterase 4 Inhibitor (R)-[11C]Rolipram PHASE1COMPLETED
Vitamin D Versus Sildenafil Citrate in Fetal Growth Restriction PHASE1COMPLETED
Antidepressant Effects on cAMP Specific Phosphodiesterase (PDE4) in Depressed Patients PHASE1COMPLETED
[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET PHASE1RECRUITING
Clinical Study for the Effectiveness of Roflumilast Treatment in COPD Greek Patients Based on Standard Clinical Practice. nanUNKNOWN
Evaluation the Topical Apremilast Nanoformulation in Treatment of Localized Plaque Psoriasis nanNOT_YET_RECRUITING
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder. nanCOMPLETED
Sildenafil Citrate Added to Low Molecular Weight Heparin and Low Dose Aspirin in High-risk Pregnancy nanWITHDRAWN
Silodosin, Tadalafil Alone vs. Silodosin Plus Tadalafil as MET for Lower Ureteric Stones nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PDE4C binder may also engage these)

ProteinNameSimilarity
O89084 — 1.000 O89084 →
P54748 — 1.000 P54748 →
P14646 — 0.997 P14646 →
PDE4B 3',5'-cyclic-AMP phosphodiesterase 4B 0.996 landscape →
Q01063 — 0.995 Q01063 →
PDE4A 3',5'-cyclic-AMP phosphodiesterase 4A 0.994 landscape →
Q3UEI1 — 0.994 Q3UEI1 →
P14270 — 0.993 P14270 →
PDE4D 3',5'-cyclic-AMP phosphodiesterase 4D 0.992 landscape →
P14644 — 0.991 P14644 →
Q3ULB5 — 0.990 Q3ULB5 →
Q9UPV7 — 0.989 Q9UPV7 →
Q5ZLK6 — 0.989 Q5ZLK6 →
Q63553 — 0.989 Q63553 →
D3YWQ0 — 0.989 D3YWQ0 →
Q8TDY4 — 0.989 Q8TDY4 →
Q2TAC6 — 0.989 Q2TAC6 →
Q99PT9 — 0.989 Q99PT9 →
Q80TF6 — 0.988 Q80TF6 →
Q9BQI7 — 0.988 Q9BQI7 →
A3KMV1 — 0.988 A3KMV1 →
Q6PFD6 — 0.988 Q6PFD6 →
Q5TKR9 — 0.988 Q5TKR9 →
Q8TBC3 — 0.987 Q8TBC3 →
MAP3K13 Mitogen-activated protein kinase kinase kinase 13 0.987 landscape →
F1MAB7 — 0.987 F1MAB7 →
A7MBB4 — 0.987 A7MBB4 →
Q17QK1 — 0.987 Q17QK1 →
Q6EEF3 — 0.987 Q6EEF3 →
Q924U5 — 0.987 Q924U5 →